Ionis to hold first quarter 2022 financial results webcast
Ionis Pharmaceuticals (Nasdaq: IONS) will host a live webcast on May 4, 2022, at 11:30 a.m. Eastern Time to discuss its first quarter financial results and update on pipeline and business progress.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ionis Pharmaceuticals (Nasdaq: IONS) will host a live webcast on May 4, 2022, at 11:30 a.m. Eastern Time to discuss its first quarter financial results and update on pipeline and business progress. This event follows over 30 years of Ionis's leadership in RNA-targeted therapies, with three marketed medicines and a strong late-stage pipeline focusing on cardiovascular and neurological areas. Access the webcast and replay details at ionispharma.com.
Positive
- Industry leader in RNA-targeted therapy with over 30 years of experience.
- Three marketed medicines and a strong late-stage pipeline.
Negative
- None.
Details
News Market Reaction – IONS
The recorded move for IONS in the trading session of this news was +4.98%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Webcast scheduled for Wednesday, May 4 at 11:30 a.m. Eastern Time
CARLSBAD, Calif., April 20, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, May 4th at 11:30 a.m. Eastern Time to discuss its first quarter financial results and report on pipeline and business progress.
The webcast may be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-hold-first-quarter-2022-financial-results-webcast-301528583.html
SOURCE Ionis Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.